{"id":4319,"date":"2025-06-03T23:03:41","date_gmt":"2025-06-03T23:03:41","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/06\/03\/biotech-news-pluvicto-regeneron-jj-cancer-research-novartis-prostate-cancer-the-reado\/"},"modified":"2025-06-03T23:03:41","modified_gmt":"2025-06-03T23:03:41","slug":"biotech-news-pluvicto-regeneron-jj-cancer-research-novartis-prostate-cancer-the-reado","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/06\/03\/biotech-news-pluvicto-regeneron-jj-cancer-research-novartis-prostate-cancer-the-reado\/","title":{"rendered":"Pluvicto pushes earlier in prostate cancer play"},"content":{"rendered":"<p>    Pluvicto pushes earlier in prostate cancer play<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p><em>Want to stay on top of the science and politics driving biotech today?\u00a0<a href=\"https:\/\/www.statnews.com\/signup\/readout\/\">Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/em><\/p>\n<p>Morning! Today, STAT\u2019s Matthew Herper chats with J&amp;J\u2019s R&amp;D chief, we see the radiopharmaceutical Pluvicto being considered earlier for prostate cancer, and more.\u00a0<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/06\/03\/biotech-news-pluvicto-regeneron-jj-cancer-research-novartis-prostate-cancer-the-reado\/?utm_campaign=rss\">Read the rest\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Meghana Keshavan<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/06\/03\/biotech-news-pluvicto-regeneron-jj-cancer-research-novartis-prostate-cancer-the-reado\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pluvicto pushes earlier in prostate cancer play Want to stay on top of the science and politics driving biotech today?\u00a0Sign up\u00a0to get our biotech newsletter in your inbox. Morning! Today, STAT\u2019s Matthew Herper chats with J&amp;J\u2019s R&amp;D chief, we see the radiopharmaceutical Pluvicto being considered earlier for prostate cancer, and more.\u00a0 Read the rest\u2026 Meghana [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2154,58,2208,2209,2176,858,2207],"tags":[2150],"class_list":["post-4319","post","type-post","status-publish","format-standard","hentry","category-biotech","category-biotechnology","category-business","category-drug-development","category-drug-prices","category-pharma","category-research","category-the-readout","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/4319"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=4319"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/4319\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=4319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=4319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=4319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}